DelveInsight has launched a new report on “Prostate Cancer – Market Insights, Epidemiology, and Market Forecast-2030”.
DelveInsight’s “Prostate Cancer – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Prostate Cancer, historical and forecasted epidemiology as well as the Prostate Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Prostate Cancer Market Report:
The total prevalent cases of Prostate Cancer in the 7MM were observed to be 6,985,331 cases in 2018, and are expected to increase during the study period (2018–2030).
The highest number of prevalent cases was observed in the United States with 3,266,625 cases in 2018 which will increase during the study period (2018–2030).
On the other hand, in EU-5 countries, the highest number of diagnosed prevalent cases of prostate cancer was found in Germany with 393,977 cases in 2020, followed by France and Italy.
Key benefits of the report:
Prostate Cancer market report covers a descriptive overview and comprehensive insight of the Prostate Cancer Epidemiology and Prostate Cancer market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Prostate Cancer market report provides insights on the current and emerging therapies.
Prostate Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Prostate Cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Prostate Cancer market.
Prostate Cancer Overview
Prostate cancer is a type of malignancy that occurs in the prostate gland, which is a part of the male reproductive system. Prostate cancer is the 3rdmost prevalent type of cancer in the US and the fourth most common worldwide.
Prostate Cancer Market
The dynamics of the Prostate Cancer market are AstraZeneca/Merck Sharp & Dohme, Bristol-Myers Squibb, Novartis, Myovant Sciences, Janssen Research & Development, Hinova Pharmaceuticals USA, Hoffmann-La Roche, Pfizer/Astellas Pharma, Clovis Oncology, Advantagene or Candel Therapeutics, Merck Sharp & Dohme, anticipated to change in the coming years owing to the expected launch of emerging therapies such as and others during the forecasted period 2018-2030.
Learn more by requesting for sample @ Prostate Cancer Market Landscape
Prostate Cancer Pipeline Therapies and Key Companies
Lynparza :AstraZeneca/Merck Sharp & Dohme
Opdivo: Bristol-Myers Squibb
Relugolix: Myovant Sciences
Niraparib: Janssen Research & Development
HC-1119: Hinova Pharmaceuticals USA
Ipatasertib: Hoffmann-La Roche
Talazoparib: Pfizer/Astellas Pharma
Rucaparib: Clovis Oncology
ProstAtak: Advantagene or Candel Therapeutics
Keytruda: Merck Sharp & Dohme
Prostate Cancer Market Drivers
Increasing Use of Biomarker Testing
Rising Geriatric Population and High Prevalence Rate of Prostate Cancer
The surge in Awareness Regarding the Treatment of Prostate Cancer
Increase in Demand for Prostate Cancer
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Prostate Cancer Patient Share (%) Overview at a Glance
5. Prostate Cancer Market Overview at a Glance
6. Prostate Cancer Disease Background and Overview
7. Prostate Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Prostate Cancer
9. Prostate Cancer Current Treatment and Medical Practices
10. Unmet Needs
11. Prostate Cancer Emerging Therapies
12. Prostate Cancer Market Outlook
13. Country-Wise Prostate Cancer Market Analysis (2017–2030)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
18. Prostate Cancer Report Methodology
19. DelveInsight Capabilities
21. About DelveInsight
“Prostate Cancer Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Prostate Cancer market. A detailed picture of the Prostate Cancer pipeline landscape is provided, which includes the disease overview and Prostate Cancer treatment guidelines.
DelveInsight’s ‘Prostate Cancer Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Prostate Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States